调整与标准化频率以确定阿尔茨海默病影像生物标志物患病率
该研究基于Mayo Clinic老化研究队列的1,646名无痴呆参与者,通过MRI评估阿尔茨海默病特征性皮质厚度和PET评估脑淀粉样蛋白沉积,并调整不参与因素后标准化至Olmsted县人群,估计了淀粉样蛋白阳性及皮质厚度降低的患病率,并分析了性别和APOE ε4携带状态的影响。
要点
- 无痴呆人群中淀粉样蛋白阳性患病率为21.1%,女性24.3%高于男性17.5%。
- 皮质厚度降低患病率为28.9%,男性30.2%略高于女性27.9%。
- A+N+患病率为11.5%,且在APOE ε4携带者中更高(16.4%)而非携带者中为10.0%。
核心结论
- 这些患病率估计有助于理解人群中淀粉样蛋白阳性和阿尔茨海默病特征性皮质厚度的年龄相关趋势,并可能用于预测老年人生物标志物的未来负担。
研究设计与样本
- 研究纳入Mayo Clinic老化研究的1,646名无痴呆参与者(平均年龄70.8岁,53.2%为男性),通过MRI评估阿尔茨海默病特征性复合皮质厚度,通过PET评估脑淀粉样蛋白积累,并调整不参与因素后标准化至明尼苏达州Olmsted县人群。
主要发现
- 淀粉样蛋白阳性患病率为21.1%(95%CI 19.1%-23.2%),女性24.3%,男性17.5%。
- 皮质厚度降低患病率为28.9%(95%CI 26.4%-31.5%),女性27.9%,男性30.2%。
- 生物标志物分类患病率:A-N-为61.4%,A+N-为9.7%,A-N+为17.4%,A+N+为11.5%。
- 男性中:A-N- 62.6%,A+N- 7.3%,A-N+ 19.9%,A+N+ 10.2%;女性中:A-N- 60.4%,A+N- 11.7%,A-N+ 15.3%,A+N+ 12.6%。
- APOE ε4携带者中:A-N- 54.6%,A+N- 16.6%,A-N+ 12.4%,A+N+ 16.4%;非携带者中:A-N- 63.3%,A+N- 6.9%,A-N+ 19.9%,A+N+ 10.0%。
临床怎么用
- 临床医生可参考这些患病率数据,结合性别和APOE ε4状态,评估无痴呆老年人中阿尔茨海默病影像生物标志物阳性的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the prevalence of elevated brain amyloid and reduced cortical thickness (as a marker for neurodegeneration) in a defined population. METHODS: Mayo Clinic Study of Aging participants underwent MRI to assess a composite Alzheimer disease (AD) signature cortical thickness measure and PET to assess brain amyloid accumulation. Participants were characterized as having elevated amyloid (A+/A-), reduced cortical thickness (N+/N-), and A+N+, A+N-, A-N+, or A-N-. The prevalence of AD biomarkers was derived by adjusting for nonparticipation and standardizing to the Olmsted County, Minnesota, population. RESULTS: Among 1,646 participants without dementia (mean age 70.8 years; 53.2% men), the prevalence (95% confidence interval) of amyloidosis was 21.1% (19.1%-23.2%): women, 24.3%; men, 17.5%. The prevalence of reduced cortical thickness was 28.9% (26.4%-31.5%): women, 27.9%; men, 30.2%. The prevalence estimates of biomarker categories were as follows: A-N-: 61.4%; A+N-: 9.7%; A-N+: 17.4%; and A+N+: 11.5%, and varied by sex and by APOE ε4 carrier status. In men, prevalence estimates were as follows: A-N-: 62.6%; A+N-: 7.3%; A-N+: 19.9%; and A+N+: 10.2%. In women, prevalence estimates were as follows: A-N-: 60.4%; A+N-: 11.7%; A-N+: 15.3%; and A+N+: 12.6%. In ε4 carriers, prevalence estimates were as follows: A-N-: 54.6%; A+N-: 16.6%; A-N+: 12.4%; and A+N+: 16.4%. In non-ε4 carriers, prevalence estimates were as follows: A-N-: 63.3%; A+N-: 6.9%; A-N+: 19.9%; and A+N+: 10.0%. CONCLUSIONS: These prevalence estimates are important for understanding age-related trends in amyloid positivity and AD signature cortical thickness in the population, and for potentially projecting the future burden of biomarkers in elderly persons.
引用
- Roberts RO, Knopman DS, Syrjanen JA, et al. Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology. 2017. PMID: 29030451. doi:10.1212/WNL.0000000000004652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。